Skip to main content
. 2010 Dec 29;43(1):60–68. doi: 10.3109/07853890.2010.538080

Figure 2.

Figure 2

Graphical depiction of the risk estimates for experiencing the primary outcome in patients with HFPEF and HFREF with increasing levels of plasma galectin-3. The distribution of (log-transformed) galectin-3 is depicted in the background in brown bars. A similar increase in galectin-3 causes a much more pronounced increase in risk in patients with HFPEF compared to patients with HFREF.